Table 5 Multivariate disease-specific survival analysis in the overall cohort under inclusion of CDX2 expression, age, gender CRC subtype, tumour budding, WHO grade, UICC stage and microsatellite status.

CDX2 subgroups

0.97

   CDX2-high

1.00

   CDX2-low/absent

1.005

0.68

1.48

WHO subtype

0.03

   Adenocarcinoma NOS

1.00

   Mucinous adenocarcinoma

1.04

0.66

1.62

   Signet-ring cell carcinoma

0.92

0.32

2.65

   Medullary carcinoma

0.14

0.02

1.07

   Micropapillary adenocarcinoma

0.92

0.68

1.25

   Serrated adenocarcinoma

1.13

0.72

1.77

   Adenoma-like adenocarcinoma

0.73

0.17

3.02

   MANEC/NEC

2.84

1.08

7.47

Tumour budding

<0.001

   Bd1

1.00

   Bd2

3.27

2.31

4.63

   Bd3

6.90

4.73

10.07

WHO grade

0.01

   Low grade

1.00

   High grade

1.37

1.07

1.77

UICC stage

<0.001

   I

1.00

   II

1.70

1.01

2.87

   III

1.79

1.06

3.02

   IV

4.89

2.86

8.36

Gender

0.74

   Female

1.00

   Male

1.04

0.82

1.32

Age group

0.02

   Below median

1.00

   Median and above

1.33

1.04

1.69

Microsatellite status

0.85

   Microsatellite instable

1.00

   Microsatellite stable

1.04

0.66

1.66